Abstract
Hemostasis is the system of generation and destruction of thrombi. It consists of coagulation and thrombolysis and has a plasmatic part and a cellular one, the latter being the thrombocytes and endothelial cells for coagulation and the polymorphonuclear granulocytes (PMN) for thrombolysis. Main products of PMN are oxidants of the hypochlorite / chloramine-type that can generate the nonradical excited oxidant singlet molecular oxygen (1ΔO2 *). Physiologically, 1ΔO2 * reacts with methionine and cysteine residues and with carbenic structures in lipids, generating dioxetanes, which upon disruption emit photons in the blue spectrum of light (380-450 nm). It modifies some important hemostasis components in blood: 1ΔO2 * inactivates the factors I (fibrinogen), V, VIII, vWF, X, plasminogen activator inhibitor-1 (PAI-1), and 1ΔO2 * oxidation of plasminogen and fibrin facilitates their specific cleavage by plasminogen activators and plasmin. Furthermore, 1ΔO2 * downregulates thrombocyte-function and upregulates PMNfunction. Chloramines seem to be the main physiologic generators of 1ΔO2 * : in concentrations of 0.1-2 mM in blood they strongly inhibit coagulation and enhance thrombolysis. The biogenesis and reaction pattern of 1ΔO2 * is of importance to understand the PMN-physiology in hemostasis, giving rise to new therapy forms of thromboatherothrombosis in man.
Keywords: Singlet-Oxygen, hemostasis, thrombi, polymorphonuclear granulocytes, thrombolysis, nonradical excited oxidant, singlet molecular oxygen
Current Vascular Pharmacology
Title: Regulation of Hemostasis by Singlet-Oxygen (1ΔO2*)
Volume: 2 Issue: 4
Author(s): Thomas W. Stief
Affiliation:
Keywords: Singlet-Oxygen, hemostasis, thrombi, polymorphonuclear granulocytes, thrombolysis, nonradical excited oxidant, singlet molecular oxygen
Abstract: Hemostasis is the system of generation and destruction of thrombi. It consists of coagulation and thrombolysis and has a plasmatic part and a cellular one, the latter being the thrombocytes and endothelial cells for coagulation and the polymorphonuclear granulocytes (PMN) for thrombolysis. Main products of PMN are oxidants of the hypochlorite / chloramine-type that can generate the nonradical excited oxidant singlet molecular oxygen (1ΔO2 *). Physiologically, 1ΔO2 * reacts with methionine and cysteine residues and with carbenic structures in lipids, generating dioxetanes, which upon disruption emit photons in the blue spectrum of light (380-450 nm). It modifies some important hemostasis components in blood: 1ΔO2 * inactivates the factors I (fibrinogen), V, VIII, vWF, X, plasminogen activator inhibitor-1 (PAI-1), and 1ΔO2 * oxidation of plasminogen and fibrin facilitates their specific cleavage by plasminogen activators and plasmin. Furthermore, 1ΔO2 * downregulates thrombocyte-function and upregulates PMNfunction. Chloramines seem to be the main physiologic generators of 1ΔO2 * : in concentrations of 0.1-2 mM in blood they strongly inhibit coagulation and enhance thrombolysis. The biogenesis and reaction pattern of 1ΔO2 * is of importance to understand the PMN-physiology in hemostasis, giving rise to new therapy forms of thromboatherothrombosis in man.
Export Options
About this article
Cite this article as:
Stief W. Thomas, Regulation of Hemostasis by Singlet-Oxygen (1ΔO2*), Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385420
DOI https://dx.doi.org/10.2174/1570161043385420 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research L-PRP/L-PRF in Esthetic Plastic Surgery, Regenerative Medicine of the Skin and Chronic Wounds
Current Pharmaceutical Biotechnology Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Ventilation During Pediatric CPR
Current Pediatric Reviews The Breath of Life: Recent Patents on Placental and Amnion Derived Cells for Treatment of Bronchopulmonary Dysplasia
Recent Patents on Regenerative Medicine Neurobehavioral Effects of β-Escin
Current Psychopharmacology Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Colloid Update
Current Pharmaceutical Design Hepatic Lipid Metabolism Disorder and Atherosclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology Human Microdialysis
Current Pharmaceutical Biotechnology The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Current and Future Approaches to the Prevention and Treatment of Staphylococcal Medical Device-Related Infections
Current Pharmaceutical Design Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Anti-Infective Agents in Medicinal Chemistry Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Gymnema sylvestre R. Br., an Indian Medicinal Herb: Traditional Uses, Chemical Composition, and Biological Activity
Current Pharmaceutical Biotechnology Wnt Signaling in Liver Cancer
Current Drug Targets